Armed with cash from a spring financing round and a rich patent portfolio, Blueshift Biotechnologies said last week that it is steaming toward a busy first quarter in 2005: The Sunnyvale, Calif., company said it plans to launch IsoCyte, its flagship product for fluorescence-based assays.

2004 has also been a busy year for Blueshift. The biotech startup secured its first private-equity financing in April, developed and sold a prototype of IsoCyte, and forged relationships with a handful of reagent companies that may serve as potential partners down the road.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.